Hansa Biopharma AB Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Hansa Biopharma AB stock has a consensus rating of "Strong Buy" and an average price target of kr 73.00. The average 1-year stock price forecast is 120.54% higher than the current stock price, while the lowest is kr 36.00 (+8.76%) and the highest is kr 103.00 (+211.18%).

Price Target: kr 73.00 (+120.54%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	kr 36.00	kr 73.00	kr 77.00	kr 103.00
Change	+8.76%	+120.54%	+132.63%	+211.18%

* Price targets were last updated on May 26, 2026.

Analyst Ratings

The average analyst rating for Hansa Biopharma AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	6	6	7
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	7	7	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates kr 103.00	Buy	Reiterates	kr 103.00	+211.18%	May 26, 2026
David Nierengarten Wedbush	Wedbush	Buy Initiates kr 69.00	Buy	Initiates	kr 69.00	+108.46%	Jan 7, 2026

Financial Forecast

Revenue This Year

674.25M

from 222.27M

203.36%

from 222.27M

Revenue Next Year

463.89M

from 674.25M

-31.20%

from 674.25M

EPS This Year

0.96

from -5.79

EPS Next Year

-5.09

from 0.96

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	33.88M	154.53M	134.09M	171.32M	222.27M	674.25M
Revenue Growth	455.56%	356.12%	-13.22%	27.76%	29.74%	203.36%
Gross Profit	18.45M	116.05M	70.95M	87.76M	138.71M	583.68M
Gross Margin	54.47%	75.10%	52.91%	51.23%	62.41%	86.57%
Operating Income	-539.58M	-576.12M	-791.16M	-632.22M	-522.58M	166.12M
Net Income	-548.28M	-611.13M	-831.72M	-807.24M	-534.11M	161.30M
EPS	-	-	-	-	-5.79	0.96
Forward PE	-	-	-	-	-	34.66
Free Cash Flow	-257.80M	-282.34M	-438.91M	-423.66M	-345.68M	1.36B
No. Analysts	-	-	-	-	-	9

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.

Revenue Forecast

Revenue	2026	2027	2028
High	1.3B
Avg	674.3M
Low	80.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	505.6%
Avg	203.4%
Low	-64.0%

EPS Forecast

EPS	2026	2027	2028
High	7.59
Avg	0.96
Low	-6.01

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-